GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:14 2024-07-15 am EDT 5-day change 1st Jan Change
1,498 GBX -1.25% Intraday chart for GSK plc -0.76% +3.30%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Second malaria vaccine launched in Ivory Coast in new milestone RE
GSK: ViiH Healthcare to present its advances in HIV CF
GSK to Move Global Headquarters in London MT
GSK moves to new global headquarters in return to central London AN
European Equities Close Higher Thursday; UK GDP Grows More Than Expected MT
GSK: first shipments of flu vaccines to the USA CF
GSK Begins Shipping Flu Vaccines Flulaval, Fluarix MT
GSK: EXPECTS TO DISTRIBUTE OVER 36 MLN DOSES OF ITS TRIVALENT IN… RE
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season CI
GSK : Deutsche Bank reiterates its Buy rating ZD
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births RE
UBS Downgrades GSK to Neutral From Buy MT
That's not so bad, is it? Our Logo
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment MT
UBS Downgrades GSK to Neutral from Buy, Cuts PT MT
ITeos Therapeutics, Inc. Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK CI
UBS cuts GSK; RBC raises Melrose Industries AN
GSK : UBS downgrades its recommendation CF
Carlsberg to buy Britvic in GBP3.3 billion deal AN
GSK : Reduced to Neutral by UBS ZD
GSK: FIRST SINGLE-DOSE MEDICINE TO PREVENT RELAPSE OF P. VIVAX M… RE
GSK launches antimalarial drug in Thailand and Brazil CF
Citigroup Trims GSK PT, Maintains Buy Rating MT
Jefferies cuts Softcat to 'underperform' AN
GSK : Deutsche Bank keeps its Buy rating ZD
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
14.98 GBP
Average target price
19.88 GBP
Spread / Average Target
+32.71%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit